Publication | Closed Access

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint InhibitorDermatologyPembrolizumab Versus IpilimumabImmunotherapyOncologyCancer TreatmentAdvanced MelanomaPhase 3